F-star, an invoX company

Biotechnology, Bispecific antibodies, Immunooncology, Immmunotherapy, Oncology
Founded in 2006
Babraham, England
http://www.f-star.com
None

About F-star, an invoX company

F-star, an invoX company, is a clinical-stage biopharmaceutical business pioneering bispecific antibodies in immunotherapy so more people with cancer can live longer and improved lives. F-star is committed to working towards a future free from cancer and other serious diseases through the use of tetravalent (2+2) bispecific antibodies to create a paradigm shift in treatments. F-star has four second-generation immunooncology therapeutics in the clinic, each directed against some of the most promising IO targets in drug development, including LAG-3 and CD137. F-star's proprietary antibody discovery platform is protected by an extensive intellectual property estate, with over 500 granted patents and pending patent applications relating to its platform technology and product pipeline. The Company has attracted multiple partnerships with biopharma targeting significant unmet needs across several areas, including oncology, immunology, and CNS.

Company Metrics

  • Employees: 51-100
  • Monthly Visits: None
  • Tech Stack: None active products

Financial Information

  • Estimated Revenue: $1M to $10M
  • Total Funding: 144.5M None
  • Last Funding: 20M None (None)
  • Funding Status: None

Technology Stack

F-star, an invoX company actively uses None products in their tech stack.

Market Presence

Industries: Biotechnology, Bispecific antibodies, Immunooncology, Immmunotherapy, Oncology

Headquarters: Babraham, England